Physician profile
Jia Son
NPI 1720869472
$1,996.01
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $1,769 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $529.22 | 2024-2025 | Farxiga, Airsupra |
| Abbvie INC. | $404.79 | 2023-2025 | Qulipta, Linzess, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $167.07 | 2024 | |
| Aimmune Therapeutics, INC. | $145.12 | 2024 | |
| Amgen INC. | $87.58 | 2024 | Repatha, Otezla |
| Lundbeck LLC | $83.06 | 2023-2025 | Rexulti, Vyepti |
| Corcept Therapeutics | $78.27 | 2024 | Korlym |
| Astellas Pharma US INC | $58.23 | 2024 | Veozah |
| Lilly USA, LLC | $55.09 | 2024 | Jardiance, Mounjaro, Zepbound |
| Gilead Sciences, INC. | $53.76 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $51.34 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Novo Nordisk INC | $48.18 | 2024 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $45.65 | 2024 | Nuzyra |
| Dexcom, INC. | $37.56 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $35.67 | 2024 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $27.00 | 2025 | Hillrom - Eli280 Cardiograph |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2024 | Rexulti |
| Mylan Specialty L.P. | $21.38 | 2024 | Yupelri |
| Ardelyx, INC. | $19.63 | 2024 | Ibsrela |
| Theracosbio, LLC | $12.30 | 2024 | Brenzavvy |
| Cequr Corporation | $12.11 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jia Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.